ArticlePharmaceuticals (Basel, Switzerland)2022

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report.

Yoichi Nishii et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.